Jean-Yves has been CEO of Anagenesis Biotechnologies since January 2014 and President since April 2015. He is President of Syndivia, a member of the Board of Directors of Peptimimesis and a member of the Scientific Advisory Board of iTeos Therapeutics, Oncodesign & Amal Therapeutics. He is also a member of the SATT Conectus Investment Committee and the Matwin Steering Committee. For two terms, he was President of the Life Sciences Competitiveness Cluster, Alsace BioValley.

Jean-Yves has more than 30 years of experience in the pharmaceutical industry and in the management of research and development projects. Before joining Anagenesis, he was Transgene’s R&D Director for 9 years. From 2002 to 2005, he launched and directed the Cancéropôle Lyon Rhône-Alpes. From 1992 to 2002, he was Director of the Pierre Fabre Centre for Immunology. From 1998 to 2002, he was Director of the Department of Immunology at the Glaxo-Wellcome Institute in Switzerland. From 1985 to 1987, he was a scientist at the Schering-Plough Research Centre in France.

Jean-Yves holds a PhD in immunology, a « Graduate Thesis » in biochemistry and has completed the Senior Management Program at London Business School in the United Kingdom. He is the author and co-author of more than 230 scientific publications and journals.

Follow Jean Yves on LinkedIn

Back to TEAM